AR068531A1 - Dosis fija por inyeccion unica para ocrelizumab (2h7). uso de rituximab. formulacion farmaceutica. kit. - Google Patents
Dosis fija por inyeccion unica para ocrelizumab (2h7). uso de rituximab. formulacion farmaceutica. kit.Info
- Publication number
- AR068531A1 AR068531A1 ARP080104116A ARP080104116A AR068531A1 AR 068531 A1 AR068531 A1 AR 068531A1 AR P080104116 A ARP080104116 A AR P080104116A AR P080104116 A ARP080104116 A AR P080104116A AR 068531 A1 AR068531 A1 AR 068531A1
- Authority
- AR
- Argentina
- Prior art keywords
- antagonist
- antibody
- use according
- pharmaceutical formulation
- administration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Uso de un antagonista de CD20 en la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, en donde el medicamento es para la administracion a un paciente humano en una infusion intravenosa (i.v.) unica, terapéuticamente eficaz, de dicho antagonista. El antagonista de CD20 preferentemente es un anticuerpo de CD20, y la enfermedad autoinmune preferentemente es artritis reumatoidea. Reivindicacion 4: El uso segun una cualquiera de las reivindicaciones de 1 a 3, en el que el antagonista del CD20 es un anticuerpo monoclonal del CD20. Reivindicacion 6: El uso segun una cualquiera de las reivindicaciones 4 o 5, en el que el anticuerpo monoclonal de CD20 es quimérico, humanizado o humano. Reivindicacion 26: El uso segun una cualquiera de las reivindicaciones de 1 a 25, en el que el anticuerpo de CD20 está destinado a la administracion en combinacion con un fármaco elegido entre el grupo formado por los fármacos antiinflamatorios no esteroideos (NSAID), los analgésicos, los glucocorticosteroides, la ciclofosfamida, el adalimumab, la leflunomida, el infliximab, el etanercept, el ofatumumab, el tocilizumab, el AME-133, el lmmu-106 y los inhibidores de COX-2. Reivindicacion 27: El uso segun una cualquiera de las reivindicaciones de 1 a 26, para administracion que contiene un segundo agente terapéutico. Reivindicacion 29: El uso segun una cualquiera de las reivindicaciones de 1 a 28, en el que el segundo agente terapéutico es el metotrexato. Reivindicacion 50: Un articulo fabricado que contiene (a) un contenedor que contiene un antagonista de CD20; y (b) un prospecto con instrucciones para tratar una enfermedad autoinmune en un sujeto humano, dichas instrucciones indican la cantidad terapéuticamente eficaz completa del antagonista del CD20 que se tiene que administrar al sujeto en forma de infusion intravenosa unica. Reivindicacion 58: Una formulacion farmacéutica que contiene una cantidad eficaz completa de un anticuerpo de CD20 en una forma apropiada para la administracion intravenosa una sola vez. Reivindicacion 59: La formulacion farmacéutica de la reivindicacion 58, en la que el anticuerpo de CD20 es la variante 2H7 A humanizada que contiene una cadena L de longitud completa de SEQ ID N°: 6 y una cadena H de longitud completa de SEQ ID N°: 7, o un fragmento de la misma. Reivindicacion 62: La formulacion farmacéutica segun una cualquiera de las reivindicaciones de 58 a 61, en la que dicha variante 2H7 A humanizada se formula a razon de 20 mg/mI de anticuerpo en histidina sulfato 10 mM, 60 mg/mI de sucrosa, 0,2 mg/mI de polisorbato 20 y agua estéril para inyeccion, de pH = 5,8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97464107P | 2007-09-24 | 2007-09-24 | |
| GBGB0718684.4A GB0718684D0 (en) | 2007-09-24 | 2007-09-24 | Treatment method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068531A1 true AR068531A1 (es) | 2009-11-18 |
Family
ID=38670460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104116A AR068531A1 (es) | 2007-09-24 | 2008-09-22 | Dosis fija por inyeccion unica para ocrelizumab (2h7). uso de rituximab. formulacion farmaceutica. kit. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2197916A1 (es) |
| JP (1) | JP2011501734A (es) |
| CN (1) | CN101809036A (es) |
| AR (1) | AR068531A1 (es) |
| CA (1) | CA2700351A1 (es) |
| CL (1) | CL2008002817A1 (es) |
| GB (1) | GB0718684D0 (es) |
| PE (1) | PE20091078A1 (es) |
| TW (1) | TW200918091A (es) |
| WO (1) | WO2009040268A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2380911T (lt) | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| CN108431038A (zh) * | 2015-10-06 | 2018-08-21 | 豪夫迈·罗氏有限公司 | 治疗多发性硬化的方法 |
| JP7166925B2 (ja) * | 2016-03-07 | 2022-11-08 | サノフィ・バイオテクノロジー | 関節リウマチを処置するための組成物及び方法 |
| MY202382A (en) * | 2017-08-08 | 2024-04-24 | Hoffmann La Roche | Obinutuzumab treatment of a dlbcl patient subgroup |
| AU2019347730A1 (en) * | 2018-09-24 | 2021-03-25 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-CD154 antibody |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2289936T1 (sl) * | 2002-12-16 | 2017-10-30 | Genentech, Inc. | Imunoglobulinske variante in njihove uporabe |
| JP2008526998A (ja) * | 2005-01-13 | 2008-07-24 | ジェネンテック・インコーポレーテッド | 治療方法 |
| BRPI0614183A2 (pt) * | 2005-07-25 | 2011-03-15 | Trubion Pharmaceuticals Inc | uso de dose única de moléculas de ligação especìficas para cd20 |
| MY149159A (en) * | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
-
2007
- 2007-09-24 GB GBGB0718684.4A patent/GB0718684D0/en not_active Ceased
-
2008
- 2008-09-16 CN CN200880108541A patent/CN101809036A/zh active Pending
- 2008-09-16 CA CA2700351A patent/CA2700351A1/en not_active Abandoned
- 2008-09-16 JP JP2010526246A patent/JP2011501734A/ja active Pending
- 2008-09-16 EP EP08804245A patent/EP2197916A1/en not_active Withdrawn
- 2008-09-16 WO PCT/EP2008/062286 patent/WO2009040268A1/en active Application Filing
- 2008-09-22 CL CL2008002817A patent/CL2008002817A1/es unknown
- 2008-09-22 PE PE2008001653A patent/PE20091078A1/es not_active Application Discontinuation
- 2008-09-22 AR ARP080104116A patent/AR068531A1/es unknown
- 2008-09-23 TW TW097136506A patent/TW200918091A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB0718684D0 (en) | 2007-10-31 |
| TW200918091A (en) | 2009-05-01 |
| CA2700351A1 (en) | 2009-04-02 |
| PE20091078A1 (es) | 2009-07-23 |
| EP2197916A1 (en) | 2010-06-23 |
| CL2008002817A1 (es) | 2009-10-16 |
| JP2011501734A (ja) | 2011-01-13 |
| CN101809036A (zh) | 2010-08-18 |
| WO2009040268A1 (en) | 2009-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6396565B2 (ja) | 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤 | |
| ES2705001T3 (es) | Tratamiento de neoplasias hematológicas con un anticuerpo anti-CXCR4 | |
| HRP20171939T1 (hr) | Formulacija protutijela i režimi terapije | |
| US20100158905A1 (en) | Combination therapy of arthritis with tranilast | |
| AR068531A1 (es) | Dosis fija por inyeccion unica para ocrelizumab (2h7). uso de rituximab. formulacion farmaceutica. kit. | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| CN111437387A (zh) | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 | |
| KR20190014117A (ko) | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 | |
| RU2010121874A (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| KR20200088857A (ko) | Il-17 길항제에 의한 화농성 한선염의 치료 | |
| JP2019218359A (ja) | Ｇｄ２陽性がんを処置するための製剤および方法 | |
| JP2022160685A5 (es) | ||
| JP2015172060A5 (es) | ||
| JP2019521156A5 (es) | ||
| JP2022536469A (ja) | ＰｃｒＶに結合する抗ＰｃｒＶ抗体、抗ＰｃｒＶ抗体を含む組成物、およびその使用方法 | |
| ES2891336T3 (es) | Combinaciones y usos de las mismas | |
| CN105813637A (zh) | 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂 | |
| WO2017076804A1 (en) | Treatment paradigm | |
| KR20200083996A (ko) | 인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법 | |
| WO2021108338A1 (en) | A combination of a btk inhibitor and abatacept for the treatment of rheumatoid arthritis | |
| TW202120546A (zh) | 使用介白素-17（il-17）拮抗劑治療狼瘡性腎炎之方法 | |
| CN115697378A (zh) | 用cgrp抑制剂治疗肺部损伤的方法 | |
| Patil et al. | Childhood occurrence of pemphigus | |
| KR20230061198A (ko) | 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법 | |
| Wakabayashi et al. | Maintenance of efficacy and safety with subcutaneous golimumab in rheumatoid arthritis patients with low disease activity who previously received TNF inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |